SLRX - Salarius Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Salarius Pharmaceuticals, Inc.

2450 Holcombe Boulevard
Suite J-608
Houston, TX 77021
United States

Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Mr. David J. ArthurCEO, Pres & Director275.15kN/A1963
Mr. Mark J. RosenblumExec. VP of Fin. & Interim CFON/AN/A1953
Mr. Sunil Sharma M.D.Chief Medical OfficerN/AN/AN/A
Mr. Scott JordanChief Bus. OfficerN/AN/A1967
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Salarius Pharmaceuticals, Inc. a clinical-stage oncology company, develops therapies for the treatment of patients with various cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. It has a collaborative partnership with The Ivy Brain Tumor Center at the Barrow Neurological Institute to to develop cancer treatment for glioblastoma. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

Corporate Governance

Salarius Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.